nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.04.2013 | Review

Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response

verfasst von: Jessica Anna Cintolo, Julia Tchou, Daniel A. Pryma

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Positron emission tomography (PET) is an imaging modality that using radiotracers, permits real-time dynamic monitoring of biologic processes such as cell metabolic behavior and proliferation, and has proven useful as a research tool for understanding tumor biology. While it does not have a well-defined role in breast cancer for the purposes of screening, diagnosis, or prognosis, emerging PET technologies and uses could expand the applications of PET in breast cancer. Positron emission mammography may provide an alternative adjunct imaging modality for the screening and diagnosis of high-risk patients unable to tolerate MRI. The development of radiotracers with the ability to measure hormonal activity could provide a non-invasive way to assess hormone receptor status and functionality. Finally, the role of PET technologies in monitoring early treatment response may prove particularly useful to research involving new therapeutic interventions.

Nur mit Berechtigung zugänglich

Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan (2013) The Warburg effect: insights from the past decade. Pharmacol Ther 137(3):318–330

Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, Siegel BA, Bradley JD (2006) 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 47(11):1808–1812PubMed

Keyes JW Jr (1995) SUV: standard uptake or silly useless value? J Nucl Med 36(10):1836–1839PubMed

Feuardent J (2004) SM, de Dreuille O. Reliability of SUV estimates in FDG PET as a function of acquisition and processing protocols. IEEE Trans Nucl Sci, Foehrenbach H

Freudenberg LS, Frilling A, Kuhl H, Muller SP, Jentzen W, Bockisch A, Antoch G (2007) Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 17(12):3139–3147PubMedCrossRef

Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G (2007) PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am 45(4):639–644, v

Lal G, Fairchild T, Howe JR, Weigel RJ, Sugg SL, Menda Y PET-CT scans in recurrent or persistent differentiated thyroid cancer: is there added utility beyond conventional imaging?. Surgery 148(6):1082–1089; discussion 1089–1090

Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL (2008) Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 15(1):286–292PubMedCrossRef

Delbeke D, Schoder H, Martin WH, Wahl RL (2009) Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med 39(5):308–340PubMedCrossRef

10.

Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, Townsend DW (2000) Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 3(6):223–230PubMedCrossRef

11.

Schoder H, Larson SM, Yeung HW (2004) PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45(Suppl 1):72S–81SPubMed

12.

Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW (2009) Impact of time-of-flight on PET tumor detection. J Nucl Med 50(8):1315–1323PubMedCrossRef

13.

Lois C, Jakoby BW, Long MJ, Hubner KF, Barker DW, Casey ME, Conti M, Panin VY, Kadrmas DJ, Townsend DW (2010) An assessment of the impact of incorporating time-of-flight information into clinical PET/CT imaging. J Nucl Med 51(2):237–245PubMedCrossRef

14.

El Fakhri G, Surti S, Trott CM, Scheuermann J, Karp JS (2011) Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med 52(3):347–353PubMedCrossRef

15.

Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW (2011) Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol 56(8):2375–2389PubMedCrossRef

16.

Levin Klausen T, Hogild Keller S, Vinter Olesen O, Aznar M, Andersen FL (2012) Innovations in PET/CT. Q J Nucl Med Mol Imaging 56(3):268–279

17.

Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, Abe K, Sasaki M (2012) Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med 53(11):1716–1722

18.

Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34(3):414–419PubMed

19.

Kubota K, Ishiwata K, Kubota R, Yamada S, Tada M, Sato T, Ido T (1991) Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32(11):2118–2123PubMed

20.

Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, Tamahashi N (1995) Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 36(3):484–492PubMed

21.

Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M et al (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery–in malignant glioma. Ann Nucl Med 18(4):291–296PubMedCrossRef

22.

Okamoto S, Shiga T, Hattori N, Kubo N, Takei T, Katoh N, Sawamura Y, Nishijima K, Kuge Y, Tamaki N (2011) Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med 25(3):213–220PubMedCrossRef

23.

Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, Shinoda J, Yano H, Iwama T (2012) Evaluation of brain tumors using dynamic 11C-methionine-PET. J Neurooncol 109(1):115–122PubMedCrossRef

24.

Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC (2012) 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 53(11):1709–1715

25.

Miwa K, Matsuo M, Shinoda J, Aki T, Yonezawa S, Ito T, Asano Y, Yamada M, Yokoyama K, Yamada J et al. (2012) Clinical value of [(11)C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors. Int J Radiat Oncol Biol Phys 84(5):1139–1144

26.

Mankoff DA, Dehdashti F, Shields AF (2000) Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2(1–2):71–88PubMedCrossRef

27.

Vanderhoek M, Juckett MB, Perlman SB, Nickles RJ, Jeraj R (2011) Early assessment of treatment response in patients with AML using [(18)F]FLT-PET imaging. Leuk Res 35(3):310–316PubMedCrossRef

28.

Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, Masson S, Walter T, Houzard C, Scoazec JY, Hervieu V et al (2011) 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours. Nucl Med Commun 32(2):91–97PubMedCrossRef

29.

Yamamoto Y, Ono Y, Aga F, Kawai N, Kudomi N, Nishiyama Y (2012) Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med

30.

Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, DeLoia JA (2011) Noninvasive assessment of cell proliferation in ovarian cancer using [18F]3’deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging. Nucl Med Biol 38(4):485–491PubMedCrossRef

31.

Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T et al (2011) A pilot study to evaluate 3’-deoxy-3’-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 52(12):1898–1902PubMedCrossRef

32.

Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC (2012) 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer 118(12):3135–3144PubMedCrossRef

33.

Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P, Heerschap A, van der Graaf WT, Grotenhuis JA, Oyen WJ (2012) 3′-Deoxy-3′-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. J Nucl Med

34.

Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N (2012) Usefulness of 3’-Deoxy-3’-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med 53(10):1521–1527PubMedCrossRef

35.

Barwick T, Bencherif B, Mountz JM, Avril N (2009) Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 30(12):908–917PubMedCrossRef

36.

Contractor K, Aboagye EO, Jacob J, Challapalli A, Coombes RC, Stebbing J (2012) Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3-deoxy-3-fluorothymidine PET: a pilot study. Biomark Med 6(2):231–233PubMedCrossRef

37.

Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, Challapalli A, Turkheimer F, Al-Nahhas A, Sharma R et al (2011) [18F]-3’Deoxy-3’-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Can Res 17(24):7664–7672CrossRef

38.

PROTOCOL ACRIN (American College of Radiology Imaging Network) 6688 http://www.acrin.org/TabID/597/Default.aspx). Accessed March 2013

39.

Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T, Krohn KA (2008) Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49(3):367–374PubMedCrossRef

40.

Verhagen A, Studeny M, Luurtsema G, Visser GM, De Goeij CC, Sluyser M, Nieweg OE, Van der Ploeg E, Go KG, Vaalburg W (1994) Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 21(7):941–952PubMedCrossRef

41.

Jonson SD, Welch MJ (1998) PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 42(1):8–17PubMed

42.

Ojasoo T, Dore JC, Gilbert J, Raynaud JP (1988) Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis. J Med Chem 31(6):1160–1169PubMedCrossRef

43.

Zhou HB, Lee JH, Mayne CG, Carlson KE, Katzenellenbogen JA (2010) Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. J Med Chem 53(8):3349–3360PubMedCrossRef

44.

Lee JH, Zhou HB, Dence CS, Carlson KE, Welch MJ, Katzenellenbogen JA (2010) Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography. Bioconjug Chem 21(6):1096–1104PubMedCrossRef

45.

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE et al (2009) NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7(10):1060–1096PubMed

46.

Reddy DH, Mendelson EB (2005) Incorporating new imaging models in breast cancer management. Curr Treat Options Oncol 6(2):135–145PubMedCrossRef

47.

CodeMap®: 2012 Medicare Physician Fee Schedule https://www.codemap.com/ge/index.cfm?cat=6&subcat=39. Accessed Sept 2012

48.

(2009) AIUM practice guideline for the performance of a breast ultrasound examination. J Ultrasound Med 28(1):105–109

49.

Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ et al (2008) Combined screening with ultrasound and mammography versus mammography alone in women at elevated risk of breast cancer. Jama 299(18):2151–2163PubMedCrossRef

50.

Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437PubMedCrossRef

51.

Lehman CD, Smith RA (2009) The role of MRI in breast cancer screening. J Natl Compr Canc Netw 7(10):1109–1115PubMed

52.

Network NCC: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 3.2012. In.; 2012

53.

Kolb TM, Lichy J, Newhouse JH (2002) Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27, 825 patient evaluations. Radiology 225(1):165–175PubMedCrossRef

54.

Bird RE, Wallace TW, Yankaskas BC (1992) Analysis of cancers missed at screening mammography. Radiology 184(3):613–617PubMed

55.

Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in breast cancer. Clin Positron Imaging 2(5):261–271PubMedCrossRef

56.

Buscombe JR, Holloway B, Roche N, Bombardieri E (2004) Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging 48(2):109–118PubMed

57.

CodeMap®: 2012 Medicare Physician Fee Schedule

58.

Kalender WA, Beister M, Boone JM, Kolditz D, Vollmar SV, Weigel MC: High-resolution spiral CT of the breast at very low dose: concept and feasibility considerations. Eur Radiol

59.

Zanzonico P, Dauer L, St Germain J (2008) Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities. Health Phys 95(5):554–570PubMedCrossRef

60.

Fahey FH, Palmer MR, Strauss KJ, Zimmerman RE, Badawi RD, Treves ST (2007) Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study. Radiology 243(1):96–104PubMedCrossRef

61.

Weigel M, Vollmar SV, Kalender WA (2011) Spectral optimization for dedicated breast CT. Med Phys 38(1):114–124PubMedCrossRef

62.

Crotty DJ, Brady SL, Jackson DC, Toncheva GI, Anderson CE, Yoshizumi TT, Tornai MP (2011) Evaluation of the absorbed dose to the breast using radiochromic film in a dedicated CT mammotomography system employing a quasi-monochromatic x-ray beam. Med Phys 38(6):3232–3245PubMedCrossRef

63.

Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS (1993) Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71(12):3920–3925PubMedCrossRef

64.

Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK, Lindsley SK, Gralow JR, Austin-Seymour MM, Ellis GK et al (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22(1):5–17PubMed

65.

Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, Andreou J (2011) The impact of FDG PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun 32(2):85–90PubMedCrossRef

66.

Sloka JS, Hollett PD, Mathews M (2005) Cost-effectiveness of positron emission tomography in breast cancer. Mol Imaging Biol 7(5):351–360PubMedCrossRef

67.

Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, Koretz K, Glatting G, Rieber A, Kreienberg R et al (2001) Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28(3):351–358PubMedCrossRef

68.

Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G, Fontanillas M, Pons F (2008) Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26(29):4746–4751PubMedCrossRef

69.

Bergkvist L, Frisell J (2005) Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br J Surg 92(10):1221–1224PubMedCrossRef

70.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546–553PubMedCrossRef

71.

Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, Spano G, Luini A, Intra M, Veronesi P et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18(3):473–478PubMedCrossRef

72.

Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J et al (2008) Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 8:165PubMedCrossRef

73.

Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, Song I, Kim Y, Lee C (2009) Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 33(5):943–949PubMedCrossRef

74.

Utech CI, Young CS, Winter PF (1996) Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23(12):1588–1593PubMedCrossRef

75.

Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A, Chiesa C, De Sanctis V, Delledonne V, Salvadori B et al (1998) Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39(1):4–8PubMed

76.

Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, Wyld L, Ingram C, Wilkinson ID, Lorenz E (2011) Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 37(3):187–198PubMedCrossRef

77.

Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, Phillips EH (2006) Preoperative FDG PET for axillary metastases in patients with breast cancer. Arch Surg 141(8):783–788; discussion 788–789

78.

van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, Meijer S, Lammertsma AA, Teule GJ (2002) Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236(5):619–624PubMedCrossRef

79.

Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK (1998) Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39(3):431–435PubMed

80.

Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, Biersack HJ (1997) Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17(3B):1687–1692

81.

Kim H, Han W, Moon HG, Min J, Ahn SK, Kim TY, Im SA, Oh DY, Han SW, Chie EK et al (2011) The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. Breast Cancer Res Treat 126(3):637–641PubMedCrossRef

82.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112(5):995–1000PubMedCrossRef

83.

Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J (2009) Alavi A. Degree of Tumor FDG Uptake Correlates with Proliferation Index in Triple Negative Breast Cancer. Mol Imaging Biol, Schnall M

84.

Hodgson NC, Gulenchyn KY (2008) Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 26(5):712–720PubMedCrossRef

85.

Minn H, Soini I (1989) [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 15(2):61–66PubMedCrossRef

86.

Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N (2008) Meta-analysis: comparison of F-18Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 33(2):97–101PubMedCrossRef

87.

Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL Jr et al (2009) 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 50(3):340–347PubMedCrossRef

88.

Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I (1998) Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16(10):3375–3379PubMed

89.

Network NCC: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 3.2012. In.; 2012

90.

NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, v.3.2012. In.: Available from: National Comprehensive Cancer Network, Fort Washington, PA.; 2012

91.

Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G et al (2012) Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 39(5):852–863PubMedCrossRef

92.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ et al (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7(2):122–192PubMed

93.

Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE (2005) Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 234(2):527–534PubMedCrossRef

94.

Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amodei L, Tafra L, Adler LP, Uddo J, Stein W 3rd et al (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer. Breast J 12(4):309–323PubMedCrossRef

95.

Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH (2000) Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 41(11):1851–1858PubMed

96.

Levine EA, Freimanis RI, Perrier ND, Morton K, Lesko NM, Bergman S, Geisinger KR, Williams RC, Sharpe C, Zavarzin V et al (2003) Positron emission mammography: initial clinical results. Ann Surg Oncol 10(1):86–91PubMedCrossRef

97.

Moadel RM (2011) Breast cancer imaging devices. Semin Nucl Med 41(3):229–241PubMedCrossRef

98.

Eo JS, Chun IK, Paeng JC, Kang KW, Lee SM, Han W, Noh DY, Chung JK, Lee DS (2012) Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. Breast 21(1):66–71PubMedCrossRef

99.

Weinberg IN (2006) Applications for positron emission mammography. Phys Med 21(Suppl 1):132–137PubMedCrossRef

100.

Berg WA, Madsen KS, Schilling K, Tartar M, Pisano ED, Larsen LH, Narayanan D, Ozonoff A, Miller JP, Kalinyak JE (2011) Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 258(1):59–72PubMedCrossRef

101.

Berg WA, Madsen KS, Schilling K, Tartar M, Pisano ED, Larsen LH, Narayanan D, Kalinyak JE (2012) Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol 198(1):219–232PubMedCrossRef

102.

Berg WA, Blume JD, Adams AM, Jong RA, Barr RG, Lehrer DE, Pisano ED, Evans WP, 3rd, Mahoney MC, Hovanessian Larsen L et al (2010) Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology 254(1):79–87

103.

Kalinyak JE, Schilling K, Berg WA, Narayanan D, Mayberry JP, Rai R, Dupree EB, Shusterman DK, Gittleman MA, Luo W et al (2011) PET-guided breast biopsy. Breast J 17(2):143–151PubMedCrossRef

104.

Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8):1287–1293PubMedCrossRef

105.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62PubMedCrossRef

106.

Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F (1986) The predictive value of estrogen and progesterone receptors’ concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 57(6):1171–1180PubMedCrossRef

107.

Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ (1996) Positron emission tomography with 2-[18F]Fluoro-2-deoxy-d-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2(6):933–939PubMed

108.

Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA (1999) Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26(1):51–56PubMedCrossRef

109.

Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19(11):2797–2803PubMed

110.

Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA (2009) PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113(3):509–517PubMedCrossRef

111.

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Jama 302(13):1429–1436PubMedCrossRef

112.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK et al (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24(18):2793–2799PubMedCrossRef

113.

Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH et al (2011) Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 17(14):4799–4805PubMedCrossRef

114.

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979PubMedCrossRef

115.

Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 126(1):185–192PubMedCrossRef

116.

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG (2009) Lub-de Hooge MN: development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50(6):974–981PubMedCrossRef

117.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN, de Vries EG Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87(5):586–592

118.

Oude Munnink TH, Dijkers EC, Netters SJ, Lub-de Hooge MN, Brouwers AH, Haasjes JG, Schroder CP, de Vries EG (2010) Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol 28(21):e355–356; author reply e357

119.

Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K, Iwase H (2012) Clinical relevance of Ki-67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast cancer (Tokyo, Japan)

120.

Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, Wada N (2013) Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and ki67 overexpression on survival. Oncology 84(3):135–140PubMedCrossRef

121.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M et al (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11(2 Pt 2):951s–958sPubMed

122.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Can Inst 99(2):167–170CrossRef

123.

von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100(8):552–562CrossRef

124.

Hylton N (2006) MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 14(3):383–389, vii

125.

Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S et al (2012) Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy–results from ACRIN 6657/I-SPY TRIAL. Radiology 263(3):663–672PubMedCrossRef

126.

Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T et al (2011) Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer 18(4):299–308PubMedCrossRef

127.

Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11(11):2101–2111PubMed

128.

Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13(6):1470–1477PubMed

129.

Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA (1996) Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37(6):931–938PubMed

130.

Duch J, Fuster D, Munoz M, Fernandez PL, Paredes P, Fontanillas M, Guzman F, Rubi S, Lomena FJ, Pons F (2009) 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 36(10):1551–1557PubMedCrossRef

131.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB (2003) Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44(11):1806–1814PubMed

132.

Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H et al (2000) Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18(8):1689–1695PubMed

133.

Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O et al (2000) Positron emission tomography using [(18)F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18(8):1676–1688PubMed

134.

Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ (2006) Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 24(19):3026–3031PubMedCrossRef

135.

Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK et al (2011) Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 11:452PubMedCrossRef

136.

Ueda S, Tsuda H, Saeki T, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Omata J, Moriya T et al (2010) Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J 16(6):660–662PubMedCrossRef

137.

Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC, Vennin P, Servent V, Fournier C, Carpentier P, Bonneterre J (2012) Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat 131(2):517–525PubMedCrossRef

138.

Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44(9):1426–1431PubMed

139.

Mankoff DA, Shields AF, Krohn KA (2005) PET imaging of cellular proliferation. Radiol Clin North Am 43(1):153–167PubMedCrossRef

140.

Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24(34):5366–5372PubMedCrossRef

141.

Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN (2009) The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 19(6):1347–1357PubMedCrossRef

Titel: Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response
verfasst von: Jessica Anna Cintolo
Julia Tchou
Daniel A. Pryma
Publikationsdatum: 01.04.2013
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2451-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy

Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer

A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase

Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis

Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis

TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie